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Abstract 
Monoclonal antibodies raised against tumor-
associated antigens have found a therapeutic niche in 
cancer treatment. Lately they have been modified 
modified either via attachment to protein toxins or 
highly potent, low-molecular-weight drugs. Such 
molecules, termed immunotoxins and antibody-drug 
conjugates (ADCs), respectively, represent a second 
revolution in antibody-mediated cancer therapy. 
Thus, highly toxic compounds are delivered to the 
interior of cancer cells based on antibody specificity 
for cell surface target antigens. This review discuss 
the processes and key considerations associated with 
preclinical and clinical development of ADCs, 
market dynamics and future projections for novel 
ADCs for the treatment of hematological 
malignancy. To date, three ADCs have been 
approved by the FDA: Gemtuzumab ozogamicin, 
Brentuximab vedotin, and ado-Trastuzumab 
emtansine (T-DM1). There are currently at least 11 
ADCs in Phase I-III clinical trials for hematological 
malignancies for which targets, antibodies, linkers, 
and cytotoxic pay loads have been disclosed. 
Key words: 
Antibody-drug conjugate (ADC), Antibodies, 
Anticancer drugs, Hematological malignancy, 
Targeted therapy, ADC development and market. 
Introduction 
Conventional therapies, such as surgery, 
chemotherapy, and radiation therapy, have shown 
some success in the battle again cancer. However, 
they are often accompanied by complex and 
sometimes, severe side- effects due to the lack of 
target specificity. To circumvent this flaw and 
improve the efficacy and safety of cancer treatment, 
targeted cancer therapies, especially antibody-drug 
conjugates (ADCs), have been actively exploited 
and they are gaining a significant amount of attention 
during the recent years (FitzGerald et al, 2011; Beck 
et al, 2012; Lambert, 2013; Mullard, 2013; Leal et al, 
2014; Diamantis and Banerji, 2016; Eighth world 
ADC Conference, 2016). The ADC technology 
utilizes the specificity of monoclonal antibodies with 
the potency of cytotoxic drug molecules, thereby 
taking advantage of the best characteristics of both 
components. 
Various ADCs have been designed for use in patients 
with hematologic malignancies, including 
lymphoma, multiple myeloma, and leukemia. 
Lymphoma is a general term for a group of cancers 
that originate in the lymphatic system and is the most 
common type of blood cancer. There are two major 
categories of lymphoma: Hodgkin lymphoma, also 
known as Hodgkin disease, and non-Hodgkin 
lymphoma. Hodgkin lymphoma is a cancer that 
starts in white blood cells called lymphocytes, which 
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are part of the body’s immune system. The disease is 
most often diagnosed in early adulthood (ages 20-40) 
and late adulthood (older than 55 years of age). 
Classical Hodgkin lymphoma is the most common 
type of Hodgkin lymphoma, accounting for 95% of 
cases. Classical Hodgkin lymphoma is distinguished 
from other lymphomas by the characteristic presence 
of CD30-positive Reed-Sternberg cells. 
 
According to the American Cancer Society, more 
than 8,000 cases of Hodgkin lymphoma will be 
diagnosed in the United States during 2017 and 
approximately 1,000 will die from the disease. 
According to the Lymphoma Coalition, over 62,000 
people worldwide are diagnosed with Hodgkin 
lymphoma each year and approximately 25,000 
people die each year from this cancer. In the 
European Union, about 12,200 new cases and 2,600 
deaths occurred in 2012 as a result of Hodgkin 
lymphoma. 
 
One of the main challenges in the development of 
novel ADCs is the identification of a cell surface 
protein that is selectively expressed  in tumors  and  
that  allows for efficient  internalization of the  
payload drug to provide a clinical benefit (Teicher, 
2009). Another challenge is to couple a highly 
specific monoclonal antibody to the appropriate 
linker–toxin combination to achieve the desired 
safety and efficacy profile (Polson et al, 2009). 
 
By design, an ADC utilizes a monoclonal antibody 
to specifically deliver the toxic payload into target 
antigen expressing tumor cells, thus reducing or 
eliminating the payload cytotoxicity to healthy 
tissues. Not all tumor proteins can serve as ADC 
targets. To do so, they must meet the following 
stringent criteria: 
 
 Cell surface localization: to allow efficient 
antibody/ADC binding. 
 Tumour specific with decent protein 
expression: ideally 100,000 antigens/solid 
tumour cell and about 5000 
antigens/hematologic cancer cell to ensure 
ADC specificity and efficacy. 
 Higher tumour surface expression: if the 
identification of a tumour specific antigen 
is proven to be difficult, a shared cell 
surface antigen can also be considered 
under the condition that it shows a much 
higher expression on cancer cell surfaces 
comparing to that on normal cells to reduce 
collateral damages.< 
 Antibody to drug ratio: 4 drug molecules 
per antibody appears optimal because it 
maintains blood half-life nearly that of the 
naked antibody, preserves antibody binding 
to the target protein, and delivers sufficient 
number of cytotoxic molecules to the target 
cell to be lethal (Hamblett et al, 2004). 
 Internalization: to ensure the ADC 
incorporation via receptor mediated 
endocytosis upon ADC binding. 
 Desired turnover time: to facilitate 
maximizing ADC efficiency and efficacy. 
 
Antibody-drug conjugates are complex bio-
macromolecules combining the accurate targeting 
capability of a monoclonal antibody with the 
extremely high cytotoxicity of a payload drug via a 
molecular linker. As a potent new candidate for next 
generation cancer immunotherapy, ADCs have been 
demonstrated both by concept and in practice to 
accurately deliver the payload drugs only to the 
antigen bearing cells, minimizing the collateral 
damage to normal tissues and reducing the side-
effects of otherwise highly toxic agents (Figure 1).  
 
Bridging an antibody and a payload drug, the 
molecular linker is a key ingredient in the formation 
of an ADC. A good linker should bear a simple 
structure and be chemically compatible with both the 
antibody and the payload drug. It not only 
contributes to the stability and solubility of the ADC, 
but also dictates the release mechanism of the 
payload drug inside the cell. Up to this date, various 
linkers with high chemical complexities have been 
exploited but they all exert certain drawbacks that 
prevent their wide application in ADC developments.  
 
FitzGerald et al, 2011 and Lambert, 2013 have 
summarized many of the initial pivotal studies that 
supported development and use of ADCs for cancer 
treatment. This review article will discuss issues 
surrounding development of ADCs for 
hematological malignancy, evidence from 
preclinical studies, current clinical trials, and future 
directions of research. 
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Figure 1. Schematic representation of the processes associated to the mechanism of action and biological 
activity of antibody drug conjugates. The monoclonal antibody component of an ADC selectively binds a cell-
surface tumor antigen, resulting in internalization of the ADC-antigen complex through the process of receptor-
mediated endocytosis. The ADC-antigen complex then traffics to lysosomal compartments and is degraded, 
releasing active cytotoxic drug inside the cell. Free drug causes cell death through either tubulin polymerization 
inhibition or DNA binding/damage depending on the drugs mechanism of action (taken from Panoski et al, 
2014)
 
Preclinical Development of ADCs 
In the developmental phase the ADC, it is evaluated 
by in vitro methods and then in animal models. The 
preclinical models are used to show ADC’s 
feasibility of the concept, safety and efficacy. 
Following Investigational New Drug (IND) or 
Biologics License Agreement (BLA) regulatory 
submission and approval, Phase I-IV clinical trials in 
cancer patients are conducted for demonstrating 
safety and therapeutic efficacy of the ADC. After 
approval of New Drug Application (NDA), ADC is 
made available to wider population of cancer 
patients through large scale manufacturing, business 
development strategies and marketing. Different 
stages of ADC development are described below. 
 
Monoclonal Antibodies against Hematological 
Malignancy 
Monoclonal antibody-based treatment of cancer has 
been established as one of the most successful 
therapeutic strategies for both hematologic 
malignancies and solid tumors in the last 20 years. 
Following the development of hybridoma 
technology by Köhler and Milstein (1975), 
combined with serological techniques and analytical 
tools, monoclonal antibodies were used to dissect the 
surface structure of human cancer cells, thus paving 
the way for the identification of cancer cell surface 
antigens suitable for targeting by antibodies. 
Antibody engineering has made breakthroughs over 
recent years making it feasible to produce 
humanized and fully human antibodies as the basic 
components of ADCs. The early generation ADCs 
used murine monoclonal antibodies causing 
significant immunogenicity, with many patients 
producing human anti-mouse antibodies thus 
reducing the efficacy of treatment. The most 
commonly used antibody format currently is human 
IgG isotypes and in particular IgG1 (Hughes, 2010; 
Perez et al, 2014). 
 
Tumor-associated antigens recognized by 
therapeutic monoclonal antibodies against 
hematologic malignancies are outlined in Table 1. 
Hematopoietic differentiation antigens are 
glycoproteins usually associated with CD groupings 
(Van den Eynde and Scott, 1998; Weiner et al, 2010; 
Chan and Carter, 2010; Cheson and Leonard, 2008; 
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Leslie and Younes, 2013; Diamantis and Banerji, 
2016). 
 
Table 1. Tumor associated antigens for 
hematological malignancies 
Antigen category 
Examples 
of antigens 
Tumor types 
expressing antigens 
Clusters of 
differentiation 
(CD) antigens 
CD19 NHL, ALL, DLBCL 
  CD22 
ALL, NHL, B-cell 
lymphoma 
  CD30 NHL, ALCL, AML, HL 
  CD33 AML 
  CD37 NHL, CLL 
  CD52 CLL 
  CD74 
CLL, NHL, Multiple 
myeloma 
  CD79b DLBCL, Follicular NHL 
  CD98 AML 
  CD138 Multiple myeloma 
Abbreviations: NHL, non-Hodgkin lymphoma; ALL, 
Acute lymphocytic leukemia; DLBCL, Diffuse large 
B- cell lymphoma; ALCL, Anaplastic large cell 
lymphoma; AML, Acute myelogenous leukemia; 
HL, Hodgkin lymphoma; CLL, Chronic 
lymphocytic leukemia. 
 
Leslie and Younes (2013) have described various 
CD antigens expressed by lymphoma (CD19, CD22, 
and CD30) and leukemia (CD22, CD33). Briefly, 
CD19 is expressed on the surface of B-lymphocytes 
throughout development with loss of expression on 
plasma cells. CD19 is rapidly internalized on binding 
with anti-CD19 antibody, MEDI-551. CD22 is 
involved in inhibitory B-cell receptor complex 
signaling and prevention of autoimmunity. Similar 
to CD19, it is rapidly internalized on antigen binding. 
CD30 is a member of the tumor-necrosis factor 
receptor family, expressed on activated T and B-
lymphocytes, and rapidly internalized on antigen 
binding. CD33 a myeloid-specific transmembrane 
receptor is found on acute myelogenous leukemia 
(AML). The cell surface target Campath-1 (CD52) is 
expressed on chronic lymphocytic leukemia cells 
(Blatt et al, 2014). 
 
Once an antigen is identified, the first step in ADC 
development project is extensive screening to 
acquire a few suitable monoclonal antibodies for 
specific target recognition (Zhang et al. 2010). Flow 
cytometry and immunohistochemistry techniques 
are typically used for confirming targeted protein 
expression on isolated cancer cell surface and on 
clinical tumor specimens fixed in paraffin sections. 
 
ADC Cytotoxic payloads 
The payload can be small drug molecules, 
radioisotopes, proteins, or bacterially/plant derived 
toxins. The payload drugs used in ADCs are highly 
toxic. They are small molecules that interact with 
intracellular targets and function as agents to block 
or disrupt crucial cellular metabolic pathways and 
eventually lead to cell death. Some payload drugs 
target tubular filaments and interfere with their 
dynamics to inhibit microtubule formation (e.g. 
Auristatins, Taxoids) or cause mitosis arrest (e.g. 
Maytansinoids). Other payloads inhibit crucial 
processes such as DNA transcription by binding to 
an important enzyme (Amatoxins bind to RNA 
polymerase) or enzyme complexes (thailanstatin A 
interacts with spliceosome complexes) to block 
transcription initiation or interfere with mRNA 
splicing, respectively. DNA itself is another bio-
macromolecule that is frequently targeted by several 
payload drugs. Some payloads interact with DNA 
minor groove and cause DNA damage by inducing 
cleavages at specific sites (Calicheamicins) or by 
reacting with certain bases (e.g. Duocarmycins 
reacts with guanine). Other than the payloads 
mentioned above, novel chemical or biochemical 
entities that trigger specific downstream processes 
and result in cell damages, including drug carriers, 
proteins with toxic effects, toxic enzymes, and small 
molecule inhibitors targeting other crucial cellular 
pathways, have also been adopted as payloads 
(Teicher, 2009; Ducry and Stump, 2010). 
 
ADC Linkers 
Linkers accommodate different conjugation 
chemistries on both antibodies and payload drugs. 
They are an important portion in an ADC because 
they not only contribute to the stability of the 
complex in systematic circulation but also dictate the 
payload release mechanisms once internalized and 
trafficked into designated cellular locations. Linkers 
are categorized based on their release mechanisms 
into cleavable linkers (peptide linkers, ß-glucuronide 
linkers, pH-sensitive linkers, and glutathione-
sensitivity linkers) and non-cleavable thioether and 
disulfide bonds (Ducry and Stump, 2010; Jain et al., 
2015). For non-cleavable linker based ADC, the 
release mechanism is believed to occur via 
internalization of the ADC followed by degradation 
of the monoclonal antibody component in the 
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lysosomes, resulting in the release of the cytotoxic 
drug (e.g. Maytansinoid drug) still attached via the 
linker to a lysine residue (Chari et al., 1992). 
 
In Vitro Efficacy Evaluation of ADCs 
Besides good specificity and binding affinity, a 
successful ADC antibody must also exert B tendency 
for internalization after antigen binding. Most of the 
toxic payloads function by disrupting important 
cellular pathways after antibody internalization via 
receptor mediated endocytosis (Panoski et al, 2014). 
Efficacy evaluation for ADC is initially performed 
by in vitro cytotoxicity assays for determining the 
surviving fractions of cell cultures by colony-
forming ability and by back-extrapolation of the 
exponential growth curves. Chari et al (1992) 
synthesized maytansinoids that had 100- to 1000- 
fold higher cytotoxic potency than clinically used 
anticancer drugs. Despite high potency, maytansine 
was ineffective in human clinical trials (Issell et al, 
1978) because of its high systemic toxicity, which 
resulted in low therapeutic index. However, when 
maytansinoids were linked to antibodies via 
disulfide bonds, which ensured the release of fully 
active drug inside the cell, the ADC conjugates 
showed high antigen-specific cytotoxicity for 
cultured human cancer cells (50% inhibiting 
concentration, 10 to 40 pM), low systemic toxicity in 
mice, and good pharmacokinetic behavior. In 
addition, when anti-CD19 antibody B4 was 
conjugated via disulfide linkers to CC-1065 potent 
small drug molecule (Chari et al, 1995) or to plant 
toxin ricin (Shah et al, 1993) proved to be extremely 
potent to human Burkitt’s lymphoma cell line 
Namalwa in antigen-specific manner. These and 
other early pivotal studies clearly demonstrated that 
ADCs proved much more cytotoxic to antigen 
expressing tumor cells than antigen-negative control 
MOLT-4 cells (acute lymphoblastic leukemia) when 
tested at the same time. 
 
In Vivo Efficacy Using Xenograft Animal Models 
for Hematological Malignancies 
To verify the efficacy of ADCs against 
hematological malignancies and to support initiation 
of clinical trials, human xenograft model in 
immunocompromised animals have been described 
for variety of human cancer cell lines (Table 2). For 
blood malignancies, subcutaneous (Kim et al, 2015) 
and systemic models (Shah et al, 1993) are the most 
common human xenograft models available. 
 
Table 2. Human cell lines used for xenograft studies 
Target (Reference) Cancer type Cell line 
CD19 NHL, ALL, diffuse Large B Cell lymphoma, non-B non-T ALL Namalwa, Nalm-6, Raji, Daudi 
CD22 ALL, NHL, B cell lymphoma Reh, SEM, NSLM6, KOPN8 
CD23 AML MOLM14, KG1 
CD25 NHL, HL KARPAS299, L-540k 
CD30 HL, ALCL, NHL, AML U937, MV4-11, HL60, MOLM-14 
CD33 Relapsed AML HL60, HEL9217, TF1-alpha, U937, KG1 
CD74 Multiple myeloma BjAB, Raji 
SAIL (Kim et al, 2015) AML OCI-AML3, THP1 
Abbreviations: NHL, non-Hodgkin lymphoma; ALL, Acute lymphocytic leukemia; AML, Acute myelogenous 
leukemia; HL, Hodgkin lymphoma; ALCL, Anaplastic large cell lymphoma. 
 
Following the creation of the human xenograft tumor 
model in immunocompromised mice (SCID) or 
other athymic mice (e.g. conventional nude mice, 
triple-deficient nude mice), clinical grading and 
observation are carried out following treatment of 
animals with the ADC regimen. Tumor growth in 
subcutaneous xenograft model is monitored by 
measuring tumor size with Vernier caliper in two 
dimensions (long and short axis). As for systemic 
xenograft model, common method is luciferase-
labeled carcinomatous cells combined with 
bioluminescent imaging system. Both animal models 
are routinely monitored for signs of diseases, 
including weight change, development of scruffy 
coat, limb paralysis, and the presence of palpable 
tumor. 
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The systemic xenograft models (survival models) are 
considered more relevant models than subcutaneous 
tumor models since they may represent disseminated 
or metastatic cancer patients. One of the early reports 
of animal survival models for evaluating therapeutic  
 
efficacy of ADC against hematological tumours was 
described by Shah et al (1993). Groups of 10 SCID 
mice were injected intravenously (i.v.) with 4 
million CD19 expressing Namalwa or Nalm-6 tumor 
cells. After 7 days, mice bearing established 
systemic tumors were treated i.v. for 5 consecutive 
days with either ant-B4-blocked ricin ADC (100 
ug/kg/day) or anti-B4 antibody as control (72 
ug/kg/day). Other controls included were untreated 
SCID mice bearing systemically growing tumors, 
isotype-matched non-specific control immunotoxin, 
N901-bR (100 ug/kg/day i.v. for 5 days), or anti-B4 
naked antibody (2 mg/kg/day i.v. for 5 days). As 
compared to untreated animal survival curves 
observed following i.v. injections of 10x fold 
different numbers of tumor cells, the ADC (anti-B4-
blocked ricin) showed tumor specific efficacy by 
killing up to 3 logs of tumor cells in SCID mice as 
evident by significant prolongation in life of the 
treated animals. Only very limited or no effects on 
animal survival was observed in animals treated with 
either anti-B4 naked antibody alone or N901-
blocked ricin non-specific control ADC. The 
difference in survival between anti-B4-bR and 
untreated or anti-B4 antibody-treated control 
animals was highly significant (p = <0.02 log-rank 
test; p = <0.01, Wilcoxon test). The Namalwa 
survival model developed by Shah et al (1993) was 
also successfully used to demonstrate therapeutic 
efficacy of another tumour specific ADC, anti-B4-
DC1 (Chari et al, 1995). In this study, highly 
cytotoxic synthetic drug CC-1065 (DC1) was 
conjugated to humanized version of anti-B4 murine 
antibody via novel cleavable disulfide linker. Groups 
of SCID mice with established Namalwa tumours 
were treated daily for 5 day via i.v. injection with 
anti- B4-DC1 at DC1 dose of 80 ug/kg/day or at DC1 
dose of 80 ug/kg/day or isotype-matched but non-
binding conjugate, N901-DC1. The anti-B4-DC1 
conjugate showed specific anti-tumour efficacy in 
the Namalwa aggressive B-cell lymphoma survival 
model in SCID mice and completely cured animals 
bearing large tumours. Anti-B4-DC1 was 
considerably more effective in this tumour model 
than doxorubicin, cyclophosphamide, etoposide, or 
vincristine chemotherapeutic drugs at their 
maximum tolerated doses. 
 
Regulatory Toxicology (Safety) & Pharmacology 
Studies for IND Submission 
Using Good Laboratory Practice (GLP) guidelines, 
the ADC is evaluated in rodents, canine, and/or non- 
human primates for pharmacokinetics, absorption- 
distribution-metabolism (ADME), safety, efficacy, 
potential mutagenicity and immunogenicity. 
 
For determining pharmacokinetic property of the 
ADC, several key parameters are measured 
including total and conjugated antibodies, free and 
conjugated drugs, as well as catabolites. For ADME 
evaluation, pharmacokinetic analysis is performed 
by assessing distribution of the radioisotope labeled 
ADC (PET scan or postmortem radioactivity 
analysis), metabolism is determined using mass 
spectrometry (LC- MS/MS) analysis of ADC 
metabolite and catabolite present in tissues, and 
excretion is determined by measuring presence of 
ADC fragments in animal excreta. 
 
Toxicological property of an ADC is evaluated 
following acute- and repeat-dose toxicity tests, 
chronic toxicity test, and tissue cross-reactivity 
under GLP-compliant test platforms. 
 
Efficacy evaluation of the ADC is usually performed 
in human tumor xenograft models as described 
previously. Detailed cage-side observations and 
pathological analysis of tissues are done to provide a 
complete profile of the ADC drug safety and efficacy. 
 
Most ADCs are generated using human monoclonal 
antibodies or humanized antibodies to minimize 
immunogenicity and the toxic payloads are usually 
not immunogenic. However, as a newly formed bio- 
macromolecule, ADCs might present unexpected 
immunogenicity, an undesired feature for ADC 
performance. 
 
Manufacturing of ADCs 
An ADC is formed by covalent biochemical 
conjugation of a monoclonal antibody with highly 
toxic payload drugs via a small molecular linker. 
ADCs are emerging candidates for targeted cancer 
therapies and due to the extreme toxicity of their 
payloads, ADCs are often considered as a new 
generation of highly hazardous and toxic 
pharmaceutical products. The unique nature of ADC 
presents challenges in its large-scale production. 
ADC manufacturing requires proper facilities that 
strictly follow the criteria and guidelines of cGMP-
standard bio-macromolecule production. These 
manufacturing facilities are extremely stringent 
about aseptic production and they need to be 
operated under an occupational exposure limit (OEL) 
below 50 ng/m3. For example, a leading contract 
research organization, Novasep (Le Mans, France), 
provides fully integrated supply chain for the cGMP 
manufacturing of ADCs, including bio-conjugation, 
payload, linker and monoclonal antibodies. Novasep 
was inspected and approved by US FDA in May 
2016. 
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ADC manufacturing is a multistep process that can 
be divided into three distinct stages: 
 
    1. CGMP production of the antibody: Therapeutic 
antibodies are manufactured initially in pilot (5- 35 
L) and then in large scale (>100 L) bioreactors using 
various expression systems such as hybridoma or 
mammalian cell lines. 
    2. CGMP synthesis of the drug-linker complex: 
Highly tailored linker molecules bearing different 
release mechanisms are synthesised. Pay load drugs 
are modified as necessary for formulating the drug-
linker complex for ADC manufacturing. 
    3. Conjugation to form an ADC: ADC conjugation 
is achieved in cGMP certified reactors after small- 
scale conjugation protocol verification. The 
therapeutic impurities are removed utilizing 
advanced filtering devices such as ultrafiltration and 
tangential flow filtration (TFF) systems and 
characterized for: 
 Structure for correct folding 
 Conjugation sites for an accurate map of 
conjugated drug-linker locations via mass 
spectroscopy along with information 
regarding the physical attachment of the 
unreacted drug-linker on the antibody 
 Drug to antibody molar ratio (DAR) and the 
distribution patter of different DAR species 
using advanced chromatography and mass 
spectroscopy analysis 
 Stability for auto-fragmentation, 
aggregation, solubility, thermal stability, 
and in vitro serum stability 
 Affinity to determine and compare the 
antigen and Fc receptor binding affinity of 
ADC to non- conjugated antibody using 
approaches such as ELISA, flow cytometry, 
or surface plasmon resonance (SPR) 
 In vitro efficacy using conventional 
antigen-bearing cultured cell lines to 
evaluate the behaviour and cytotoxicity of 
an ADC 
 ADC product formulation testing is usually 
evaluated as sterile solution and as 
lyophilized formulation. Sterile ADC 
solution is less expensive to manufacture, 
often frozen at -80 degrees C, and therefore 
needs complicated cold chain management. 
Lyophilized ADC may give better stability 
but it requires more complicated 
development and is therefore more 
expensive to manufacture. 
 
The ADC product is finished by filling into aseptic 
vials via the cGMP sterile filling pipeline. 
 
Clinical Development of ADCs 
Traditional cancer chemotherapy leads to systemic 
toxicity in the patient. Monoclonal antibodies 
against antigens on cancer cells offer an alternative 
tumor-selective treatment. However, monoclonal 
antibodies on their own do not kill cancer cells. 
Therefore, antibody–drug conjugates uses antibodies 
to deliver a potent cytotoxic compound selectively to 
tumor cells, thus improving the therapeutic index of 
chemotherapeutic agents. 
 
To date, three ADCs were approved by the FDA: 
Gemtuzumab ozogamicin, Brentuximab vedotin, 
and ado-Trastuzumab emtansine (T-DM1). 
Gemtuzumab ozogamicin was initially approved by 
FDA in 2000 for the treatment of relapsed CD33-
positive acute myeloid leukemia in older patients not 
considered candidates for standard chemotherapy 
(Bross et al, 2001). However, it was withdrawn from 
the market after further studies which showed no real 
benefit (FDA press release, 2013). Brentuximab 
vedotin was approved in 2011 for the treatment of 
relapsed or refractory Hodgkin’s lymphoma and 
relapsed or refractory systemic anaplastic large-cell 
lymphoma (Gopal et al, 2012; Pro et al, 2012; Senter 
and Sievers, 2012). Finally, the most recent ADC 
newcomer is T-DM1 for use in metastatic HER2-
positive breast cancer (FDA Approval, 2013; Oostra 
and Macrae, 2014). Approval of these ADCs has 
spurred tremendous research interest in this field. 
 
The FDA approved ADC for hematological 
malignancy, Brentuximab vedotin (Adcetris, Seattle 
Genetics) is composed of an anti-CD30 monoclonal 
antibody connected with a cleavable peptide to the 
highly potent tubulin inhibitor MMAE. CD30 is a 
member of the tumour necrosis factor (TNF) family 
identified on Reed–Sternberg cells of classical 
Hodgkin lymphoma (HL). Binding of Adcetris to the 
cell surface leads to internalization and lysosomal 
proteolytic cleavage of the linker releasing the 
MMAE (Senter and Sievers, 2012; Sievers and 
Senter, 2013). Adcetris has gained approval for the 
treatment of patients with relapsed or refractory 
CD30 HL following autologous stem cell transplant 
(ASCT) or patients not legible for ASCT who have 
failed at least two other chemotherapy treatments. 
Brentuximab vedotin has also been approved for 
patients with anaplastic large cell lymphoma (ALCL) 
as a second line. The accelerated approval for 
Hodgkin’s lymphoma was based on a single-arm 
phase II clinical trial, where there was a 73% 
response rate, 32% complete remission and a median 
duration 20.5 months (Younes et al, 2012). The 
indication for ALCL was established based on the 
impressive results of the phase II study. Patients in 
this study had an 86% overall response rate and 54% 
complete responses (Pro et al, 2012). The most 
common adverse reactions were peripheral sensory 
neuropathy, neutropenia, fatigue, nausea and 
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thrombocytopenia. In USA, Brentuximab vedotin 
carries a black box warning for progressive 
multifocal leukoencephalopathy (Younes et al, 
2012). 
 
Clinical trials for ADCs against hematological 
malignancies have increased significantly in recent 
years. There are currently at least 11 ADCs in Phase 
I-II clinical trials for hematological malignancies for 
which targets, antibodies, linkers, and cytotoxic pay 
loads have been disclosed (Table 3). Most ADCs 
(8/11) in clinical development utilize humanized or 
fully human monoclonal antibodies. There are 2 
ADCs that incorporate chimeric monoclonal 
antibodies, Indatuximab ravtansine (BT062), an 
anti-CD138 ADC, and Brentuximab vedotin, and 
anti-CD 30ADC. There are 5 ADCs that use 
monomethyl auristatin as the cytotoxic compound 
and 3 ADC that employ maytansine which causes 
mitosis arrest. Of the 11 ADCs in clinical 
development, 6 ADCs are in Phase II-III 
development and 5 ADCs are in Phase I 
development. This or next year, a market approval 
could become a reality for Inotuzumab ozogamicin. 
Currently, a marketing authorization application 
from Pfizer for acute lymphocytic leukemia (ALL) 
is being reviewed for Inotuzumab ozogamicin by 
EMA. 
 
 
Table 3. Clinical development of antibody-drug conjugates for treating hematological malignancy
Antibody-Drug 
Conjugate 
Target 
Antigen 
Antibody Linker 
Cytotoxic 
Compound 
Targeted 
Disease 
Clinical 
Stage 
Developer 
Brentuximab 
vedotin 
CD30 Ch IgG1 Valine-citrulline MMAE 
HL, 
ALCL 
Approved 
marketed 
Takeda/Seattle 
Genetics 
Inotuzumab 
ozogamicin 
CD22 Hz IgG4 Hydrazone Calicheamicin NHL, LL Phase III Pfizer 
Coltuximab 
ravtansine 
CD19 Hz IgG1 
Hindered disulfide 
SPDB 
Maytansine 
DM4 
ALL, 
DLBCL 
Phase II ImmunoGen 
Pinatuzumab 
vedotin 
(RG7593) 
CD22 
Human 
IgG1 
Valine-citrulline MMAE DLBCL Phase II Genentech 
DEBIO1562/ 
IMGN529 
CD37 Hz IgG1 SMCC 
Maytansine 
DM1 
NHL Phase II 
Debiopharm/ 
ImmunoGen 
Polatuzumab 
vedotin 
(RG7596) 
CD79b Hz IgG1 Valine-citrulline MMAE NHL Phase II 
Genentech/ 
Roche/Seattle 
Genetics 
Indatuximab 
ravtansine 
(BT062) 
CD138 Ch IgG4 SPDB-DM4 
Maytansine 
DM4 
MM Phase II 
Biotest/ 
ImmunoGen 
SGN-CD19B CD19 
Not 
Identified 
Not Identified PBD NHL Phase I Seattle Genetics 
Brentuximab 
Vedotin+che-
motherapy 
CD30 Ch IgG1 Valine-citrulline MMAE 
Relapsed 
AML 
Phase I 
Massachusetts 
General Hospital 
AGS67E CD37 
Human 
IgG2 
‘Protease-cleavable 
linker’ 
MMAE 
NHL, 
CLL, 
AML 
Phase I Agensys 
BMS-936561 
(MDX-12030) 
CD70 
Human 
IgG 
Valine-citrulline Duocarmycin NHL Phase I 
Bristol-Meyers 
Squibb 
 
Antibody-Drug Conjugates For the Treatment of 
Hematological Malignancy 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(3)  120 
 
GSK2857916 BCMA Hz IgG1 Maleimidocaproyl MMAF MM Phase I GlaxoSmithKline 
Abbreviations: BCMA, B-cell maturation antigen; Ch, Chimeric; Hz, Humanized; SPDB, N-succinimidyl 3- (2-
pyridyldithio)butyrate; SMCC, 4-(N-Maleimidomethyl) cyclohexanecarboxylic acid N- hydroxysuccinimide ester; 
MMAE, Monomethyl auristatin E; PBD, pyrrolobenzodiazepine; MMAF, Monomethyl auristatin F; HL, Hodgkin 
lymphoma; ALCL, Anaplastic large cell lymphoma; NHL, Non- Hodgkin’s Lymphoma; LL, Lymphocytic 
Leukemia; ALL, Acute lymphocytic leukemia; DLBCL, Diffuse large B-cell lymphoma; MM, Multiple myeloma. 
Source: Clinicaltrials.gov: September 13, 2017; Developer company websites as of September 17, 2017; Sawas, 
2017; Owonikoko et al 2016; Cohen et al, 2016; Jain et al, 2015; Pereira et al, 2015; Chari et al, 2014; Rostami et 
al, 2014; Trail, 2013; Leslie and Younes, 2013; Teicher and Chari, 2011. 
 
Market Dynamics for ADCs 
Since the commercialization of the first therapeutic 
monoclonal antibody product in 1986, as of 
November 2014, forty-seven naked monoclonal 
antibody products were approved in US and Europe 
for the treatment of variety of diseases. At an 
approval rate of 4 new monoclonal antibody 
products per year, approximately 70 antibody 
products could be on the market by 2020, and 
combined world-wide sales could be nearly $125 
billion (Ecker et al, 2015). 
 
Two ADCs, Brentuximab vedotin (Adcetris®) and 
ado-Trastuzumab emtansine (Kadcyla®) have been  
 
approved by the US Food and Drug Administration. 
Brentuximab Vedotin (Adcetris by Seattle Genetics) 
was approved by the FDA in 2011 as the first new 
therapeutic option for patients with Hodgkin 
lymphoma in more than 30 years. Brentuximab 
Vedotin has now become the standard of care for 
relapsed Hodgkin lymphoma, with more than 20,000 
patients treated, as noted by Jonathan Drachman, 
M.D., Chief Medical Officer and Executive Vice 
President, Research and Development of Seattle 
Genetics. Brentuximab Vedotin is an antibody-drug 
conjugate directed to CD30, a defining marker of 
classical Hodgkin lymphoma, which combines the 
targeting ability of a monoclonal antibody, attached 
by a protease-cleavable linker to the cell-killing 
microtubule disrupting agent, monomethyl auristatin 
E (MMAE). The drug employs a linker system that 
is designed to be stable in the bloodstream but to 
release MMAE upon internalization into CD30-
expressing tumor cells. In 2014, ado-trastuzumab 
(Kadcyla®by Genentech) was approved by the FDA 
to treat Her2-positive breast cancer, representing the 
first ADC drug for solid tumors. 
 
There are more than 50 ADCs at various stages of 
clinical development, covering a broad spectrum of 
oncology targets (Beck et al, 2012; Mullard, 2013). 
The market for ADCs was worth approximately $1.3 
billion in 2016 with just two approved marketed 
drugs, and its potential remains very large. Total 
revenues, representing product sales (collaboration 
and royalty revenues are not considered), are 
expected to be $4.2 billion worldwide by 2021 at a 
CAGR of 25.5% from 2016 through 2021. Glyco- 
engineering should help with better selection of 
monoclonal antibodies through optimal 
pharmacokinetic, potency and toxicity profiles (Shah, 
2014). Glyco-engineering will undoubtedly play 
major part in further development of better target 
specific monoclonal antibodies and thus on the ADC 
market as a whole. 
 
Further Development of ADCs for Cancer 
Treatment: 
The ADC space continues to develop as knowledge 
and innovative technologies strive to improve the 
therapeutic window of ADCs. Despite the clinical 
success of Adcetris® and Kadcyla®, the field still 
faces challenging tasks, such as improving targeted 
delivery efficiently, minimizing systemic toxicity, 
and tackling drug resistance (Loganzo et al, 2016). 
Insufficient understanding of ADCs mechanism of 
action, inadequate knowledge of the management 
and understanding of ADCs off-target toxicities, and 
difficulties in the selection of suitable clinical 
settings such as patient selection, dosing regimen are 
some possible explanations for the slow clinical 
translation of new ADCs. 
 
As a complex entity containing three components 
(monoclonal antibody, linker, and chemical drug), 
the function of ADCs is highly sensitive to each 
component’s attributes. Their clinical outcomes can 
be further improved by optimizing target selections, 
binding moieties (monoclonal antibody and protein 
scaffolds), cytotoxic drugs, linkers, conjugation sites, 
and conjugation chemistries. As many novel ADC 
technologies mature over time, we expect to see a 
generation of safer and more effective ADCs for 
clinical translation and commercialization in the 
future. With further developments in antigen, 
effector, and linker technology, the specificity and 
efficacy of ADCs will continue to improve, creating 
valuable agents for both monotherapy and 
combination therapy in hematologic malignancies. 
Additionally, further correlative biomarker studies 
will be crucial to improve patient selection for ADCs 
against hematological and other malignancies. 
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Summary and Conclusions: 
In summary, the search for “magic bullets” that can 
potently eradicate cancer without damaging normal 
tissues continues unabated. Antibody–drug 
conjugates are one of the fastest growing classes of 
oncology therapeutics. After half a century of 
research, the approvals of brentuximab vedotin and 
trastuzumab emtansine have paved the way for 
ongoing clinical trials that are evaluating more than 
50 further ADC candidates. The limited success of 
first-generation ADCs (developed in the early 2000s) 
informed strategies to bring second-generation 
ADCs to the market, which have higher levels of 
cytotoxic drug conjugation, lower levels of naked 
antibodies and more-stable linkers between the drug 
and the antibody. Furthermore, lessons learned 
during the past decade are now being used in the 
development of third-generation ADCs. 
 
In this review, I have discussed the current strategies 
for developing ADCs against hematological 
malignancy and other cancers. This included 
selection of target antigens as well as suitable 
cytotoxic drugs; the design of optimized linkers; 
preclinical development; clinical trials and toxicity 
issues. The selection and engineering of antibodies 
for site-specific drug conjugation, which will result 
in higher homogeneity and increased stability, as 
well as the quest for new conjugation chemistries 
and mechanisms of action, are priorities in future 
ADC research and development. One important 
issue that may have to be addressed is the 
development of host resistance to ADCs, similar to 
mixed drug resistance (MDR) observed for 
chemotherapeutic drugs. Lorenzo and co-workers 
(2016) have suggested that the modular nature of the 
ADC will allow components to be switched and 
replaced, enabling development of second-
generation ADCs that overcome acquired resistance. 
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